Recurrent hyperkalemia in patients with chronic kidney disease and hepatitis C treated with direct antiviral agents

Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4-5 chronic kidney disease (CKD) needs further observation in real world. Thirty-three patients with stage 5 CKD and hepatitis C virus (HCV) infection from 2 hemod...

Full description

Saved in:
Bibliographic Details
Published in:BMC infectious diseases 2019-06, Vol.19 (1), p.550-550, Article 550
Main Authors: Yan, Taotao, Wang, Jiuping, Li, Juan, Fu, Shan, Chen, Yi, Hu, Chunhua, Zhang, Rou, Tian, Zhen, Zhao, Fahui, Dong, Jun, Liu, Jinfeng, Yang, Yuan, Chen, Tianyan, Zhao, Yingren, He, Yingli
Format: Article
Language:English
Subjects:
Antiviral agents
Care and treatment
Case Report
Chronic kidney disease
Chronic kidney failure
Drug therapy
Hemodialysis
Hepatitis C
Hepatitis C virus
Hyperkalemia
Infection
Kidney diseases
Recurrence (Disease)
Risk factors
Safety and security measures
Sofosbuvir
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sofosbuvir is the keystone of direct antiviral agents for the chronic hepatitis C (CHC). The safety of sofosbuvir in patients with stage 4-5 chronic kidney disease (CKD) needs further observation in real world. Thirty-three patients with stage 5 CKD and hepatitis C virus (HCV) infection from 2 hemodialysis centers accepted sofosbuvir based treatment as we reported previously. Serum potassium concentrations were tested every 4 weeks or on demand. Ten of 33 patients showed recurrence of hyperkalemia. We summarized the characteristics of hyperkalemia occurrence in these 10 patients. Overall, 24 episodes of hyperkalemia were observed in these 10 patients, 21 were under treatment and 3 were after treatment. Patients with or without hyperkalemia before sofosbuvir treatment didn't show significantly differences in the median frequencies of hyperkalemia episodes during the observation period (3.5 vs. 2, p = 0.264). Patients with stage 5 CKD and HCV infection treated with sofosbuvir based regimens, even halved sofosbuvir, should be taken caution and closely monitoring serum potassium and renal function is necessary.
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-019-4117-x